Kenya BioVax Institute Limited (KBI)

What Kenya BioVax Institute Limited (KBI) does

Kenya BioVax Institute Limited (KBI) is a Kenyan state-affiliated entity, founded in 2022 and headquartered in Nairobi, operating under the government domain biovax.go.ke. The organization's name and institutional framing — "BioVax Institute" — indicate a focus on biologics and vaccines, consistent with Kenya's broader policy objective of building domestic vaccine manufacturing and bio-product capacity. KBI is currently a small organization of 17 employees, suggesting an early-stage buildout typical of newly established state-backed institutes. The legal entity form ("Institute Limited") and government domain extension point to incorporation under a public-sector mandate rather than as a commercial private venture.

The source material does not disclose KBI's product portfolio, manufacturing capabilities, technology stack, partnerships, revenue model, management team, or funding sources. The official website returned only a loading/verification placeholder during data capture, providing no substantive operational detail. As a result, the institute's specific functional scope — whether it conducts fill-and-finish, active pharmaceutical ingredient production, R&D, distribution, or a combination — cannot be verified from available sources. The .go.ke domain strongly implies Government of Kenya ownership or sponsorship, but no parent organization, ministry affiliation, or board governance details are documented in the captured content.

From a commercial standpoint, no pricing models, customers, distribution channels, certifications, or strategic transactions are disclosed. KBI appears to operate in a pre-revenue or government-grant-funded posture consistent with a newly established public-sector institute rather than a commercially active private business. Any investment-grade assessment of the entity's business model, market position, or revenue mechanics cannot be substantiated beyond its institutional identity and Kenyan public-sector affiliation.

Name

Kenya BioVax Institute Limited (KBI)

Legal name

Kenya BioVax Institute Limited

Website

https://biovax.go.ke

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Kenya BioVax Institute Limited is a state-affiliated Nairobi-based entity founded in 2022 under a Kenyan government domain, focused on biologics and vaccines, operating with a small 17-employee team at an early institutional buildout stage.

Ownership category

akta.pro rank

Product category

Vaccine Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Biologic API/Drug Substance Manufacturing Services (HLAAAKAA)

akta.pro secondary industries

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Immunization & Vaccination Programs Administration (BPAIAJAD)

Keywords

• Vaccine manufacturing
• Biopharmaceutical production
• Human vaccines
• Biological products
• Fill finish services

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Others

Core offering

Kenya BioVax Institute Limited (KBI) is a Kenyan state-affiliated biopharmaceutical manufacturing entity established in 2022 to develop, produce, and supply human vaccines and related biological products for domestic and regional health needs. The institute is positioned to support local vaccine manufacturing capacity, including fill-finish operations and formulation, primarily serving public-sector immunization programs and partners.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Expansion highlights3 records

Broad incumbents

• Aspen Pharmacare: Africa's largest pharmaceutical manufacturer; operates Johnson & Johnson COVID vaccine fill-finish and has broad African distribution. A more established, broader-portfolio incumbent in the same African pharmaceutical manufacturing space.
• Serum Institute of India: World's largest vaccine manufacturer by doses; supplies African immunization programs through UNICEF/GAVI. Sets global benchmarks on cost and scale that any new African entrant must compete against for tender wins.
• Sinovac Biotech: Major Chinese vaccine manufacturer active in African vaccine supply and technology-transfer discussions. Represents the type of international partner a state-backed African entrant may partner with or compete against.
• Bharat Biotech: Major Indian vaccine developer and WHO-prequalified manufacturer that has engaged with African manufacturers on tech-transfer. A likely competitor or partner for any new African vaccine institute.

Direct peers

• VACSERA: Egyptian state-owned biologics and vaccine manufacturer with established production across human vaccines and diagnostics. Comparable African state-affiliated biologics platform serving a large domestic immunization program.
• Institut Pasteur de Dakar: Senegalese nonprofit foundation operating a WHO-prequalified yellow fever vaccine facility and expanding into fill-finish for multiple antigens. Most directly comparable African state-affiliated vaccine manufacturer targeting regional supply.
• Biovac: South African state-linked vaccine manufacturer with established fill-finish, tech-transfer partnerships (e.g., with Sanofi, Pfizer), and a longer operating history. Closest analogue in business model and African government-anchored mandate.

Emerging players

• Afrigen Biologics and Vaccines: South African biotech hosting the WHO mRNA Technology Transfer Hub and developing locally formulated mRNA vaccines. Comparable emerging African biologics platform with strong public-sector backing.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/kenya-biovax-institute-limited-kbi

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kenya BioVax Institute Limited (KBI)